Adma Biologics (ADMA) Liabilities from Discontinued Operations (2025)
Adma Biologics' (ADMA) quarterly Liabilities from Discontinued Operations came in at 2647000.0 in Q4 2025.
Powered by 
Analysis
Adma Biologics (ADMA) Liabilities from Discontinued Operations (2025) Analysis & Trends
Adma Biologics (ADMA) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 2647000.0 in Q4 2025.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 2647000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 2647000.0 (changed N/A YoY) and the FY2025 annual result came in at 2647000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations steadied at 2647000.0 in Q4 2025.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 2647000.0 in Q4 2025 to a low of 2647000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.18 Bn | 2.04 Bn | 86.28 Mn |